Arthur HillerChief Corporate Development Officer at Nuritas
Arthur has extensive experience across a wide range of functional areas and segments of the life sciences industry. He has been CEO of two early-stage life sciences companies in the medical device and drug discovery areas. His current engagements include roles as part-time CEO for Antyllus Therapeutics, a cardiovascular company discovering therapeutics to treat abdominal aortic aneurysms, and consultant and business advisor for Amasa Therapeutics and Smith Therapeutics, companies developing stem-cell based treatments for patients with glioblastoma, and cell-based therapeutics for neurodegenerative disease, respectively. Through his consulting company, Hiller Life Sciences Strategies, LLC, he also provides commercial strategy consulting for a wide variety of companies, including recent engagements with a venture-backed company developing an obesity/pre-diabetes product, an early-stage microbiome company, a melanoma-focused oncology company, major multinational pharma companies launching new products in women's health and rare diseases, and an early stage diagnostic company developing a noninstrument based flow cytometry product. Previously, as CEO of Cambridge-based SciFluor Life Sciences, LLC, a private-equity backed company utilizing fluorine chemistry to improve characteristics of drug molecules, Arthur negotiated an expanded license agreement with Harvard University, and recruited an elite management and chemistry team that filed IP and began preclinical development of 13 new compounds for use in treating CNS diseases, infectious disease, and inflammatory and ophthalmic conditions. In his prior CEO role at Heartscape Technologies, he successfully launched a novel electrocardiogram (ECG) technology clinically proven to identify heart attacks not visible to the 12-lead ECG, raised $22M in B-round funding, and built a highperforming, successful team. He sold Heartscape to the medical device division of a Fortune 1000 company in early 2010. Arthur has also held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies. At Millennium, he was Senior Vice President, responsible for the cardiovascular business unit, including sales and marketing of INTEGRILIN®, new product marketing for the Millennium pipeline, and customer segment and channel management. He joined Millennium in 2001 as General Manager, Inflammation, and was subsequently named General Manager, Cardiovascular in 2002, and Senior Vice President, Global Strategic Marketing in 2003. While at Merck as Vice President, Worldwide Human Health Marketing, Hospital Products, Arthur was involved in the global launch of AGGRASTAT® (tirofiban HCI), global marketing leadership of PRIMAXIN® (Imipenem) and pre-launch development of INVANZ® (ertapenem sodium) and CANCIDAS® (caspofungin acetate). He was also responsible for Merck managed care initiatives outside the United States, and served as Senior Vice President, Business Development for Merck-Medco Managed Care, where he focused his efforts on the conceptualization and execution of numerous alliances with pharmaceutical manufacturers to support and expand Merck-Medco disease management programs. Arthur holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University, serves as Lecturer and faculty member of the Healthcare Ventures class and the IMPACT Innovation program at MIT, and in Advisory Board, fundraising, and business development capacities for a wide range of start-up and early stage companies in the Boston area.